TEL AVIV, VANCOUVER, ISRAEL/CANADA, December 29, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or “Company”), a biotechnology company The company, which is focused on discovering and developing new psychedelic-derived treatments to solve major undertreated health problems, announced at its shareholders’ meeting on December 28, 2022. I am pleased to announce all matters that have been submitted before shareholders for consideration and approval (“As set forth in the Company’s Management Information Circular dated November 28, 2022, the Company’s Vehicle Option Plan Approved by a requisite majority of the votes cast at the meeting, including an increase in the amount of approvals and options, and the amount of restricted stock units and underlying common stock issuable pursuant to the Company’s restricted stock unit plan increase of.
About Clearmind Medicine
Clearmind is a psychedelic pharmaceutical biotechnology company focused on the discovery and development of new psychedelic-derived therapeutics to solve a wide range of underserved health problems, including alcohol use disorders. I guess. Its primary purpose is to research and develop psychedelic-based compounds and commercialize them as regulated drugs, foods, or supplements.
The company’s intellectual portfolio currently consists of seven patent families. The company intends to seek additional patents for its compounds whenever warranted, and remains opportunistic in acquiring additional intellectual property to build its portfolio.
Clearmind shares are listed on the Nasdaq and Canadian Stock Exchanges under the symbol “CMND” and on the Frankfurt Stock Exchange under the symbol “CWY”.
See below for more information. https://www.clearmindmedicine.com or contact:
Investor information
Investment@clearmindmedicine.com
Phone: (604) 260-1566
General inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
